Maxim Biomedical Appoints Tony Falvo as Vice President of Strategic Partnerships

ROCKVILLE, Md., February 23, 2026 — Maxim Biomedical, Inc., a leading U.S.-based developer and manufacturer of rapid diagnostic and immunoassay platforms, today announced that Tony Falvo has joined the company as Vice President of Strategic Partnerships.

In his new role, Falvo will drive MaximBio’s strategic partnerships, supporting the company and its partners as we continue to deliver excellent U.S.-based development and manufacturing of immunoassays at-scale.

Falvo brings over two decades of commercial leadership experience in diagnostics.  His experience includes serving as National Director of Public Health & Government Strategy at Quest Diagnostics, and as National Commercial Director of Infectious Disease at OraSure Technologies.

“I am excited that Tony Falvo has joined MaximBio as our VP of Strategic Partnerships,” said Jonathan Maa, Chief Executive Officer of Maxim Biomedical. “We have been fortunate to benefit from Tony’s partnership over the past year, and couldn’t be happier that he is joining our team full-time. Tony’s deep experience building partnerships to bring diagnostics to market at scale will be instrumental as we continue to deliver for our customer and our partners.”

About Maxim Biomedical, Inc.
Headquartered in Rockville, MD and focused on U.S. manufacturing, Maxim Biomedical partners with leading healthcare companies and government agencies to develop and manufacture innovative diagnostic solutions that improve patient outcomes worldwide. For more information, visit https://maximbio.com.